Ecoland International, Inc. (ECIT) awarded new contract, shares rise

Posted on: December 5th, 2011
Written by:
admin

Shares of Ecoland International, Inc. (OTCBB: ECIT) climbed 16 percent on Moncontract from Johnson Controls on Monday after the Arizona-based company announced that it was awarded a contract from Johnson Controls (NYSE: JCI) exceeding $1.2 million, to be delivered over the next four months.

ECIT shares touched a high of $0.43 in morning trading on Monday, up from Friday’s closing price of $0.37.

According to a December 5 press release, the newly awarded project “signals the beginning of the second phase of Johnson Controls’ production relocation project,” which Ecoland’s subsidiary, D&R Technology has participated and “played an important role in for the last twelve months.”

The project “demonstrates the success of our business strategy and the confidence of our customer in our ability,” said D&R’s president Drasko Karanovic in the December 5 press release. “It is flattering to be one of the companies that helped Johnson Controls’ achieve best ever financial results for the past year. Our objective for the next period is to maintain and further develop this mutually beneficial relationship. Johnson Controls is world’s market leader in automotive seating with about 45% of the market. We see tremendous potential for our growth by simply satisfying their needs in the global market.”

For the three months ended August 31, Ecoland reported sales of $3,376, and a net loss of $47,730.

In early November, the company announced that it closed the acquisition of D&R Technology, Inc. Pursuant to the share exchange agreement, D&R’s shareholders will receive a majority share ownership in ECIT and it is anticipated that a name change will be made reflecting this change in majority share ownership. Also, according to the share exchange agreement, D&R’s management team will assume operational and managerial control effective immediately, a November 7 press release stated.

D & R Technology Inc. provides engineering, design and the manufacturing of automated tube processing solutions for the automotive industry.

no comments

Positron Corp. (POSC) soars on news of $38 million bonds award

Posted on: September 21st, 2011
Written by:
admin

Molecular imaging company, Positron Corp. (OTCBB: POSC) was up more than 49 percent in mid-day trading on Wednesday, after the company announced that the Indiana Finance Authority approved its $38 million Midwestern Disaster Area Bond volume cap application.

Shares of Positron touched a daily high of $0.029, in mid-day trading on Wednesday, up from Tuesday’s closing price of $0.0181.

According to a September 21 press release, the bonds will be a part of an overall long-term strategic investment Positron is making in its proposed high energy 70 MeV cyclotron project and radiopharmaceutical manufacturing facility in Noblesville, Indiana.

Positron is a molecular imaging company focused on Nuclear Cardiology. Positron  provides innovative molecular technologies and services that are reshaping the field of nuclear cardiology through proprietary PET imaging and radiopharmaceutical solutions with a strong commitment to advancing the practice and technology of nuclear medicine.

no comments

Generex Biotechnology Corp. (GNBT) spins out, stock points higher

Posted on: September 15th, 2011
Written by:
Glenn

Generex Biotechnology Corp. (OTCBB: GNBT) saw its shares gain 8.7% to 9.89 cents, as Thursday’s markets closed, on news of the spinout of one of its subsidiaries. Volume for the stock was 1.3 million shares, nosing out its full-day average.

A news release dated Sept. 15 announced that the company, based in Worcester, Mass., provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc.

The Company is in the midst of a detailed and comprehensive review of several transaction opportunities, including both shell companies and operating biotech companies with synergistic intellectual properties, in each case Securities and Exchange Commission registrants and Depository Trust Company eligible companies, into which Antigen Express will be merged.

Generex CEO Mark Fletcher, “We are undertaking our due diligence examination of available alternatives with a view to identifying an appropriate transaction for the Antigen Express spinout.

“We will proceed with expedition to negotiate an agreement with the target company, complete the merger of Antigen Express into that company, and conduct an initial fund raising. If the merger and the initial fund raising are successful, we will then seek a listing of the merged company’s stock on a national stock exchange.”

Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.

no comments

Phototron Holdings (PHOT) boosts sales, stock leaps

Posted on: September 15th, 2011
Written by:
Glenn

Phototron Holdings (OTCBB: PHOT) shares climbed 138.5% to 31 cents on word of exciting sales figures. Volume for the stock topped 25,000, or at least double its all-day average.

A news release put out Sept. 7 revealed that the company had increased sales by more than 78% during August, entering the second month of its new direct selling business model. August’s strong performance represented $107,000 of unaudited sales compared to approximately $60,000 of unaudited sales in July.

Phototron’s new direct selling business model will help expand Phototron’s future sales capabilities to harness the untapped demand for its innovative turn-key hydroponic gardening system.

The same release quoted CEO Doug Braun thus: “We are extremely pleased with Phototron’s results in our second full month after implementing our new business model and strategic growth initiatives.

“Significant increases in both sales and Phototron’s new affiliates demonstrate that our product and business opportunity are attractive to our target audience. In transition periods, it typically takes time to gather momentum. Now that Phototron is starting to see positive results we are confident that we will continue to see accelerated growth as we begin to focus our energies on leveraging our exciting products and new business model to consumers across the US and worldwide.”

The new direct sales model, initiated in June, represents Phototron’s new direct sales initiatives, which are expected to serve both the $30-billion home gardening market and the $1.7-billion medical marijuana community.

Phototron Holdings, Inc., based in Woodland Hills, Calif., designs and manufactures cutting-edge indoor mini-greenhouses capable of growing herbs, vegetables, flowers, fruits and terrestrial plants stronger and faster than traditional farming methods.

no comments

Bioheart Inc. (BHRT) has breakout day over FDA OK

Posted on: September 14th, 2011
Written by:
Glenn

Bioheart Inc. (OTCBB: BHRT) leaped 15.3% to 8.3 cents Wednesday on word of a clinical program the company was engaging in, using adipose cells. Volume for the stock topped 8.1 million near Wednesday’s close.

A news release issued Sept. 14 declared that the company out of Sunrise, Florida announced that they will begin a U.S. clinical program called the ANGEL trial utilizing adipose derived cells or LipiCell for congestive heart failure patients. Using the clinical data from a Phase I/II trial in Mexico and preclinical studies, Bioheart will apply to the Food and Drug Administration (FDA) to begin a Phase I study in the US.

In collaboration with the Regenerative Medicine Institute of Tijuana, Mexico, six congestive heart failure patients have been successfully treated in a Phase I/II trial at Hospital Angeles Tijuana.

The therapy involves the use of stem cells derived from the patient’s own fat (adipose tissue) obtained using liposuction. These patients have demonstrated on average, an absolute improvement of 13 percentage points in ejection fraction and an increase of 100 meters in their six-minute walk distance.

The U.S. ANGEL trial design and results from the Mexico trial were presented by Bioheart’s Chief Scientific Officer, Kristin Comella at the Stem Cells USA & Regenerative Medicine Congress in Boston this week. She was quoted in the same release as saying, “Safety and efficacy have been successfully demonstrated in the trial at Hospital Angeles and we are looking forward to beginning one of the first U.S. trials using adipose derived cells for congestive heart failure patients.”

Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.

no comments

Coldwater Creek Inc. (CWTR) shares vault on CEO stock buy

Posted on: September 14th, 2011
Written by:
Glenn

Coldwater Creek Inc. (Nasdaq: CWTR) shares spiked 14.8% to $1.63 Wednesday approaching noon ET, on news Tuesday of a stock purchase by its CEO. Volume for the stock topped two million shares, compared to an all-day average of 887,000.

An article posted Sept. 13 on the site Seeking Alpha mentioned that in recent days Dennis Ponce purchased over 600,000 shares at an average price of around 90 cents. The story also said pointed out that Coldwater Creek has seen quarterly net sales decrease to $181.4 million compared to $253 million in the same quarter in 2010.

Gross profit margins tightened for the quarter as well. Gross profit came in at $45.3 million for the quarter or 25% of net sales, compared with $84.7 million, or 33.4% of net sales in the same quarter in 2010.

The piece in Seeking Alpha added the company recently announced a three-part plan to turn it around, the key elements of which consist of a comprehensive brand marketing campaign, retail store optimization and a merchandising revitalization plan.

Coldwater Creek is a leading specialty retailer of women’s apparel, gifts, jewelry, and accessories founded in 1984 and headquartered in Sandpoint, Idaho.

no comments


About Penny Stocks

The term "penny stocks," also known as micro-cap equities, micro caps, small caps, pink sheets, refers to shares in a company that trades for less than $5.00. Most penny stocks trade on the OTCBB market and the pink sheet electronic quotation service. Penny Stocks can be very volatile and can see gains as much as 500% in a day. Volatility in penny stocks is also dangerous because penny stocks can come down as quickly as they go up. If you trade penny stocks based on stock picks, make sure to always do your due diligence on the companies you're considering, use stop loss orders, and book your profits when you are in a position to do so.